Dr. Shaltiel joins a prestigious lineup of speakers presenting applications of exosomes, including representatives from leading exosome companies such as Abbvie, Evox Therapeutics and Capricor Therapeutics, as well as senior-level executives in the field. As a pioneer and leader in this field, Dr. Shaltiel is well-positioned to provide perspective on exploiting advances in exosomes for drug delivery. NurExone is developing a first exosome-loaded nanodrug, ExoPTEN, for patients who suffer acute Spinal Cord Injuries.
Exosomes Europe is a premier event that brings together experts from academia and industry to discuss new data and case studies on advancing exosome products from the clinical stage to commercialization. The conference will take place on June 5-6, 2024, in London, England. To learn more about the summit and to register, please visit the Conference Website.